IRLAB Enters Collaboration Agreement with Danish Biotech Company Biomia ApS Applying the Integrative Screening Process (ISP)
IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that it has entered into a collaboration with the Danish biotech company Biomia to evaluate Biomia's drug candidates applying IRLAB's discovery platform, the Integrative Screening Process (ISP)."We are excited to enter into an ISP-based collaboration with Biomia, giving us the opportunity to leverage our...
Read more








